Orion abandons new COMT inhibitor
Finnish drugmaker the Orion Corp has announced its decision not to continue development of new catechol-O-methyltransferase inhibitor as it does not believe the candidate will outperform existing products.
The compound has progressed to the end of Phase I clinical trials, but results failed to show a statistically-significant advantage for the drug over existing equivalents.
In 1998, Orion launched enctacapone, a COMT enzyme inhibitor to enhance the effects of levodopa in treating Parkinson's disease. The drug went on to become Orion's lead product worldwide. It was hoped that the new enzyme in development would achieve similar status.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze